FDA approves new Alzheimer’s treatment regimen
28th January 2025 Uncategorised 0Patients and care partners may find once every four weeks maintenance dosing easier More: FDA approves new Alzheimer’s treatment regimen Source: News
read more
Patients and care partners may find once every four weeks maintenance dosing easier More: FDA approves new Alzheimer’s treatment regimen Source: News
read moreAmgen reached a settlement with Celltrion, putting a bout of patent litigation to bed and allowing the South Korean company to launch its biosimilar versions of Amgen’s bone blockbusters Prolia and Xgeva as early as June 1. The settlement appears
read moreUnder an executive order, the United States Agency for International Development is temporarily prohibited from delivering lifesaving drugs to its partner countries. More: Trump's foreign aid freeze threatens global HIV, malaria drug supply from USAID: reports Source: fierce
read moreThe FDA has cleared AstraZeneca and Daiichi Sankyo’s Enhertu as the first HER2-directed treatment for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies. More: AZ, Daiichi's Enhertu nabs 7th FDA nod,
read moreActivist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan. 25 deadline, Bloomberg reported Monday. A Starboard-backed director—or two—would have given the investor more leverage as it attempts to influence Pfizer’s turnaround strategy.
read moreThe company’s board of directors unanimously rejected partner Biogen’s $469 million buyout proposal, finding that it “significantly undervalues” the company and is not in the best interest of shareholders. More: No deal: Sage rejects Biogen's buyout offer, scouts for strategic
read more© 1994 - 2026 B.M. Pharmaceuticals